

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

30 Jul 2026

### Effect of red beetroot on metabolic factors in subjects with pre-diabetes

#### Protocol summary

##### Study aim

To examine the effect of consuming red beetroot powder on metabolic factors in people with pre-diabetes.

##### Design

Clinical trial with a control group and parallel design, double-blind, randomized, phase 3 on 74 patients. The WinPepi software was used for randomization.

##### Settings and conduct

Beetroot has the potential to be effective and therapeutic in people with pre-diabetes. People with pre-diabetes who refer to Isfahan Endocrine and Metabolism Research Center and meet the inclusion criteria will be invited to participate in this research. After obtaining informed consent, people will be asked to refer to the Endocrine and Metabolism Research Center in a fasting state of at least 8 hours during their next visit (first visit), and fasting and two-hour blood glucose samples, as well as blood and urine samples necessary for Biochemical measurements will be collected. Besides, information on anthropometrics, demographics, blood pressure, general characteristics, food intake and physical activity will be collected. At the end of week 12 (second visit), all measurements from the first visit will be repeated. During the study, the participants, the trained questioner, and the outcome examiner will be blinded to the type of intervention. For blinding, the sachets of both intervention and placebo groups will be identical in terms of shape, color, weight and other physical characteristics.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: people with prediabetes aged 20-80 years old. Non-Inclusion criteria: use of any anti-diabetic agent except metformin; pregnant or lactating women.

##### Intervention groups

Intervention: Red beetroot powder. Placebo: Rice powder

##### Main outcome variables

Main outcomes: 2-hour blood glucose level; fasting blood sugar; fasting insulin; hemoglobin A1C; homeostatic model assessment for insulin resistance; the quantitative insulin-sensitivity check index

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20221220056876N1**

Registration date: **2023-01-02, 1401/10/12**

Registration timing: **prospective**

Last update: **2023-01-02, 1401/10/12**

Update count: **0**

##### Registration date

2023-01-02, 1401/10/12

##### Registrant information

##### Name

Elham Hosseini

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 31 3792 3183

##### Email address

hosseini@res.mui.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2023-01-21, 1401/11/01

##### Expected recruitment end date

2024-04-20, 1403/02/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Effect of red beetroot on metabolic factors in subjects

with pre-diabetes

**Public title**  
Effect of red beetroot in subjects with pre-diabetes

**Purpose**  
Treatment

**Inclusion/Exclusion criteria**  
**Inclusion criteria:**  
Age 20-80 years old BMI 18-35 kg/m2  
**Exclusion criteria:**  
People with type 1, type 2, or gestational diabetes mellitus Use of any anti-diabetic agent except metformin Taking medication that affects glucose metabolism such as glucocorticoids, less than eight weeks before the start of the study Receiving growth hormone in less than six months before the start of the study Allergy to beetroot consumption A smoker or a history of smoking and alcohol consumption in the previous two years History of cardiovascular diseases (open heart surgery, cardiac congestion, heart failure, and uncontrolled blood pressure), liver cirrhosis/liver transplant, and/or kidney disease (CKD) History of inflammatory diseases such as rheumatoid arthritis A history of hypothyroidism or hyperthyroidism History of suffering from severe digestive diseases or mental illnesses Having often physical activity (more than 5 hours a week) Taking antioxidant supplements or hormonal treatments 4 weeks before the study Pregnant or lactating women

**Age**  
From **20 years** old to **80 years** old

**Gender**  
Both

**Phase**  
3

**Groups that have been masked**

- Participant
- Outcome assessor
- Data analyser

**Sample size**  
Target sample size: **74**

**Randomization (investigator's opinion)**  
Randomized

**Randomization description**  
In this study, the participants are randomly assigned to two groups of consuming beetroot powder (intervention) or placebo group. For randomization, the WinPepi software was used and the participants of each group (intervention and placebo) were placed in two strata (metformin users and non-users). The number of participants in each stratum was determined based on the prevalence of metformin use in prediabetic people. In the output of the software, the sequence of participants in two strata was determined, and in each stratum, the participants have been assigned to the intervention or placebo group. After randomization, the list of generated codes was deleted.

**Blinding (investigator's opinion)**  
Double blinded

**Blinding description**  
For blinding, intervention sachets will be similar to placebo sachets in terms of shape, texture, color, weight,

and other physical characteristics. The intervention sachets contain beetroot powder and the placebo sachets contain rice powder, which has been prepared at the same color as the beetroot powder using an approved food color.

**Placebo**  
Used

**Assignment**  
Parallel

**Other design features**

## Secondary Ids

1

**Registry name**  
**Secondary trial Id**  
**Registration date**  
empty

## Ethics committees

1

**Ethics committee**  
**Name of ethics committee**  
Ethics Committee of Isfahan University of Medical Sciences  
**Street address**  
Hezar Jerib  
**City**  
Isfahan  
**Province**  
Isfahan  
**Postal code**  
8174673461  
**Approval date**  
2022-08-22, 1401/05/31  
**Ethics committee reference number**  
IR.ARI.MUI.REC.1401.087

## Health conditions studied

1

**Description of health condition studied**  
Prediabetes  
**ICD-10 code**  
R73.02  
**ICD-10 code description**  
Impaired glucose tolerance (oral)

## Primary outcomes

1

**Description**  
2-hour blood glucose  
**Timepoint**  
At the baseline and after 12 weeks  
**Method of measurement**

Enzyme calorimetry method

## 2

### **Description**

Fasting blood sugar

### **Timepoint**

At the baseline and after 12 weeks

### **Method of measurement**

Enzyme calorimetry method

## 3

### **Description**

Fasting insulin

### **Timepoint**

At the baseline and after 12 weeks

### **Method of measurement**

The enzyme-linked immunosorbent assay

## 4

### **Description**

Hemoglobin A1C

### **Timepoint**

At the baseline and after 12 weeks

### **Method of measurement**

Enzyme calorimetry method

## 5

### **Description**

Homeostatic model assessment for insulin resistance

### **Timepoint**

At the baseline and after 12 weeks

### **Method of measurement**

Calculated by formula

## 6

### **Description**

The quantitative insulin-sensitivity check index

### **Timepoint**

At the baseline and after 12 weeks

### **Method of measurement**

Calculated by formula

## **Secondary outcomes**

## 1

### **Description**

Triglyceride

### **Timepoint**

At the baseline and after 12 weeks

### **Method of measurement**

Enzyme calorimetry method

## 2

### **Description**

Total cholesterol

### **Timepoint**

At the baseline and after 12 weeks

### **Method of measurement**

Enzyme calorimetry method

## 3

### **Description**

Low density lipoprotein

### **Timepoint**

At the baseline and after 12 weeks

### **Method of measurement**

Enzyme calorimetry method

## 4

### **Description**

High density lipoprotein

### **Timepoint**

At the baseline and after 12 weeks

### **Method of measurement**

Enzyme calorimetry method

## 5

### **Description**

High sensitivity-C Reactive Protein

### **Timepoint**

At the baseline and after 12 weeks

### **Method of measurement**

The enzyme-linked immunosorbent assay

## 6

### **Description**

Glutathione

### **Timepoint**

At the baseline and after 12 weeks

### **Method of measurement**

The enzyme-linked immunosorbent assay

## 7

### **Description**

Total antioxidant capacity

### **Timepoint**

At the baseline and after 12 weeks

### **Method of measurement**

The enzyme-linked immunosorbent assay

## 8

### **Description**

Total oxidative stress

### **Timepoint**

At the baseline and after 12 weeks

### **Method of measurement**

The enzyme-linked immunosorbent assay

## 9

### **Description**

Alanine transaminase

### **Timepoint**

At the baseline and after 12 weeks

**Method of measurement**  
Enzyme calorimetry method

## 10

**Description**  
Aspartate aminotransferase  
**Timepoint**  
At the baseline and after 12 weeks  
**Method of measurement**  
Enzyme calorimetry method

## 11

**Description**  
Alkaline Phosphatase  
**Timepoint**  
At the baseline and after 12 weeks  
**Method of measurement**  
Enzyme calorimetry method

## 12

**Description**  
Gamma-glutamyltransferase  
**Timepoint**  
At the baseline and after 12 weeks  
**Method of measurement**  
Enzyme calorimetry method

## 13

**Description**  
The Fibrosis-4 score  
**Timepoint**  
At the baseline and after 12 weeks  
**Method of measurement**  
Calculated by formula

## 14

**Description**  
Serum creatinine  
**Timepoint**  
At the baseline and after 12 weeks  
**Method of measurement**  
Kinetic Jaffe calorimetry

## 15

**Description**  
Urine creatinine  
**Timepoint**  
At the baseline and after 12 weeks  
**Method of measurement**  
Kinetic Jaffe calorimetry

## 16

**Description**  
Blood urea nitrogen  
**Timepoint**  
At the baseline and after 12 weeks  
**Method of measurement**

Enzyme calorimetry method

## 17

**Description**  
Urine microalbumin  
**Timepoint**  
At the baseline and after 12 weeks  
**Method of measurement**  
The enzyme-linked immunosorbent assay

## Intervention groups

### 1

**Description**  
Intervention group: Red beetroot powder prepared by Pak Shilan Negin Salamat private company located in Chaharmahal and Bakhtiari province, producing all kinds of fruit powder, summer vegetables, and dried vegetables, 7 grams twice a day (14 grams daily) for 12 weeks. (3 months), it is eaten with yogurt, salad, or a meal during lunch and dinner.

**Category**  
Treatment - Other

### 2

**Description**  
Control group: Rice powder prepared by Pak Shilan Negin Salamat private company located in Chaharmahal and Bakhtiari province, producing all kinds of fruit powder, summer vegetables, and dried vegetables, 7 grams twice a day (14 grams daily) for 12 weeks (3 months ), it is eaten with yogurt, salad, or a meal during lunch and dinner.

**Category**  
Placebo

## Recruitment centers

### 1

**Recruitment center**  
**Name of recruitment center**  
Isfahan Endocrine and Metabolism Research Center  
**Full name of responsible person**  
Mansour Siavash  
**Street address**  
Khorram Street  
**City**  
Isfahan  
**Province**  
Isfahan  
**Postal code**  
8187698191  
**Phone**  
+98 31 3335 9933  
**Email**  
emrc@mui.ac.ir  
**Web page address**  
<https://emrc.mui.ac.ir/en/node/1120>

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Gholamreza Askari

**Street address**

Hezar jerib Ave.

**City**

Isfahan

**Province**

Isfahan

**Postal code**

8174673461

**Phone**

+98 31 3668 7898

**Fax****Email**

research@mui.ac.ir

**Web page address**

<https://research.mui.ac.ir/fa/sitemap>

**Grant name**

570000056

**Grant code / Reference number**

240112

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Esfahan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

## Person responsible for general inquiries

**Contact****Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Elham Hosseini

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

hezar jerib Ave.

**City**

Isfahan

**Province**

Isfahan

**Postal code**

8174673461

**Phone**

+98 31 3792 3183

**Email**

hosseini@res.mui.ac.ir

**Web page address**

<https://nfsrc.mui.ac.ir/fa/sitemap>

## Person responsible for scientific inquiries

**Contact****Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Elham Hosseini

**Position**

Assistant professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

Hezar Jerib Ave.

**City**

Isfahan

**Province**

Isfahan

**Postal code**

8174673461

**Phone**

+98 31 3792 3183

**Email**

hosseini@res.mui.ac.ir

**Web page address**

<https://nfsrc.mui.ac.ir/fa/sitemap>

## Person responsible for updating data

**Contact****Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Elham Hosseini

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

□Nutrition and Food Security Research Center,  
Department of Clinical Nutrition, School of Nutrition  
and Food Science, Isfahan University of Medical  
Sciences, Hezar Jerib Ave.

**City**

Isfahan

**Province**

Isfahan

**Postal code**  
8174673461  
**Phone**  
+98 31 3792 3183  
**Fax**  
**Email**  
hosseini@res.mui.ac.ir

## Sharing plan

### **Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

### **Study Protocol**

No - There is not a plan to make this available

### **Statistical Analysis Plan**

Yes - There is a plan to make this available

### **Informed Consent Form**

Yes - There is a plan to make this available

### **Clinical Study Report**

Yes - There is a plan to make this available

### **Analytic Code**

Yes - There is a plan to make this available

### **Data Dictionary**

Yes - There is a plan to make this available

### **Title and more details about the data/document**

All data from this research can be shared after de-identifying individuals.

### **When the data will become available and for how long**

3 months after the results are published.

### **To whom data/document is available**

All researchers.

### **Under which criteria data/document could be used**

Data requests will be considered only after the publication of results.

### **From where data/document is obtainable**

The main research executor: Elham Hosseini E-mail address: hosseini@res.mui.ac.ir

### **What processes are involved for a request to access data/document**

After the publication of the results, people intending to use data collected in this research can make their request by submitting their proposal to the main executor. If the proposal is accepted by the executor, the data will be provided to the requester.

### **Comments**